Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colitis, Ulcerative 1

Interventions

etrolizumab 5Infliximab 4Adalimumab 3golimumab 2CT-P13 2peficitinib 1Sutures 1Surgical Instruments 1Ringer's Lactate 1Proctectomy 1Pneumococcal Vaccines 1Papillomavirus Vaccines 1Methylprednisolone 1Mesalamine 1Lysine Acetyltransferase 5 1Laparoscopy 1Injections 1Hydroxyethyl Starch Derivatives 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Eicosapentaenoic Acid 1CVD protocol 1ABX464 12-(3',4'-dihydroxyphenyl-1-azo)benzimidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colitis, Ulcerative × ABX464 × Clear all
NCT03760003 2025-11-28

Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis

Abivax S.A.

Phase 2 Completed
355 enrolled 39 charts

Colitis, Ulcerative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡